Bispecific CD19/CD20 CAR T-Cell Therapy Fast Tracked for SLE, Lupus Nephritis
Rheumatology Advisor,
The Food and Drug Administration (FDA) has granted Fast Track designation to IMPT-514, a bispecific CD19/CD20-targeting…
The Food and Drug Administration (FDA) has granted Fast Track designation to IMPT-514, a bispecific CD19/CD20-targeting…
The Food and Drug Administration (FDA) has granted Fast Track designation to IMPT-514, a bispecific CD19/CD20-targeting…